专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2011050052A2 PROTEIN AGENT FOR DIABETES TREATMENT AND BETA CELL IMAGING 审中-公开
标题翻译：用于糖尿病治疗和细胞成像的蛋白剂
公开(公告)号：WO2011050052A2
公开(公告)日：2011-04-28
申请号：PCT/US2010/053361
申请日：2010-10-20
申请人： GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. , LIU, Zhi-Ren , YANG, Jie , XU, Bing , ZHOU, Wangda , XUE, Shengui
发明人： LIU, Zhi-Ren , YANG, Jie , XU, Bing , ZHOU, Wangda , XUE, Shengui
IPC分类号： C07K19/00 , A61K38/26 , A61K49/14 , G01N33/52 , A61P3/10
CPC分类号： A61K38/26 , A61K38/00 , A61K47/60 , A61K49/085 , C07K14/605 , C07K2319/00
摘要： Glucagon-like peptide-1 (GLP-1 ) is a member of a large family of incretin hormones secreted in nutrient-dependent response. GLP-1 acts on GLP-1 receptor (GLP-1 R) that is highly expressed on pancreatic β-cells. The peptide has great potential for development of diabetes treatment and diagnosis. However, the pharmaceutical effects of the peptide suffer from in vivo instability and short life due to degradation by Dipeptidylpeptidase-1 (DPP-4). The 30 amino acid peptide GLP-1 has been integrated into a stable host protein human calbindin D9k. The fusion protein binds to GLP-1 R as demonstrated by immunostaining analyses of GLP-1 R expressing cells. The fusion protein agents can be useful for both diabetes treatment and GLP-1 R receptor targeting MR imaging. The fusion protein has a size about 14 kDa, which enables efficient tissue penetration and retention, and an extended circulation time, is stable, remaining intact and retaining activity after 48 hours incubation with 75% human serum. The protein retains its native folded structure after boiling for ten minutes forming the basis of an experimental protocol for large scale production of the fusion protein (>30 mg/l bacterial culture). No toxicity has been observed with tests on mice. One aspect of the disclosure, therefore, provides a fusion protein comprising a first peptide characterized by selectively binding to a site of a target cell and linked to a second peptide, where the fusion protein is more stable than the first peptide alone. In embodiments of this aspect of the disclosure, the fusion protein may further comprise a detectable label attached thereto. In some embodiments of this aspect of the disclosure, the first peptide of the fusion protein may be glucagon-like peptide-1 (GLP-1 ), glucagon-like peptide-1 (GLP-1 )(7-36), or glucagon-like peptide-1 (GLP-1 ) (9-36), or a conservative variant thereof.
摘要翻译：胰高血糖素样肽-1（GLP-1）是营养依赖性反应中分泌的大肠激素的成员之一。 GLP-1作用于在胰腺β细胞上高表达的GLP-1受体（GLP-1R）。该肽具有发展糖尿病治疗和诊断的巨大潜力。然而，由于二肽基肽酶-1（DPP-4）的降解，肽的药物作用遭受体内不稳定性和短寿命。 30个氨基酸的肽GLP-1已经被整合到稳定的宿主蛋白人类calbindin D9k中。如通过GLP-1R表达细胞的免疫染色分析所证明的，融合蛋白与GLP-1R结合。融合蛋白剂可用于糖尿病治疗和靶向MR-1的受体受体。融合蛋白具有约14kDa的大小，其能够有效的组织穿透和保留，并且延长的循环时间是稳定的，在75％人血清孵育48小时后保持完整和保留活性。蛋白质在煮沸10分钟后保持其天然折叠结构，形成大规模生产融合蛋白（> 30mg / l细菌培养物）的实验方案的基础。在小鼠试验中没有观察到毒性。因此，本公开的一个方面提供了包含第一肽的融合蛋白，其特征在于选择性结合靶细胞的位点并连接到第二个肽，其中融合蛋白比单独的第一个肽更稳定。在本公开的该方面的实施方案中，融合蛋白还可包含附着于其上的可检测标记。在本公开的该方面的一些实施方案中，融合蛋白的第一肽可以是胰高血糖素样肽-1（GLP-1），胰高血糖素样肽-1（GLP-1）（7-36）或胰高血糖素样肽-1（GLP-1）（9-36）或其保守变体。

52. 发明申请

WO2007084952A3 SYSTEMS AND METHODS FOR DRYING A ROTATING SUBSTRATE 审中-公开
公开(公告)号：WO2007084952A3
公开(公告)日：2007-07-26
申请号：PCT/US2007/060709
申请日：2007-01-18
申请人： AKRION TECHNOLOGIES, INC. , LIU, Zhi, Lewis , KASHKOUSH, Ismail , LEE, Hanjoo
发明人： LIU, Zhi, Lewis , KASHKOUSH, Ismail , LEE, Hanjoo
IPC分类号： F26B11/00
摘要： A method of drying a surface of a substrate is provided. The method includes supporting and rotating a substrate; applying a liquid to the substrate surface at or near a rotational center point via a liquid dispenser (so that a film of the liquid is formed on the surface); applying a drying fluid to she substrate surface at a predetermined distance from the rotational center point via one or more drying fluid dispensers; and manipulating the drying fluid dispenser(s) so that the location at which the drying fluid is applied to the substrate is moved in a direction toward the rotational center point, while at the same time manipulating the liquid dispenser so that the location at which the liquid is applied to the substrate is moved in a direction outward from the rotational center point. The liquid dispenser and drying fluid dispensers) noted above can be located on and/or within an assembly. The assembly can include a first dispenser, a second dispenser, and a third dispenser. The first dispenser supplies liquid while the second and third dispensers supply drying fluid, where the second dispenser has a larger opening than the third dispenser. The second and third dispensers are positioned on the assembly next to one another and spaced from the first dispenser. Further, the second dispenser is located between the third dispenser and the first dispenser, such that the first dispenser is capable of linearly leading the second and third dispensers during movement.

53. 发明申请

WO2007030802A3 TARGETED CONTRAST AGENTS AND METHODS FOR TARGETING CONTRAST AGENTS 审中-公开
公开(公告)号：WO2007030802A3
公开(公告)日：2007-03-15
申请号：PCT/US2006/035221
申请日：2006-09-08
申请人： GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. , YANG, Jenny, J. , LIU, Zhi-Ren
发明人： YANG, Jenny, J. , LIU, Zhi-Ren
IPC分类号： A61K49/14
摘要： A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.

54. 发明申请

WO2007030802A2 TARGETED CONTRAST AGENTS AND METHODS FOR TARGETING CONTRAST AGENTS 审中-公开
标题翻译：针对对象代理的目标对象代理和方法
公开(公告)号：WO2007030802A2
公开(公告)日：2007-03-15
申请号：PCT/US2006035221
申请日：2006-09-08
申请人： UNIV GEORGIA STATE RES FOUND , YANG JENNY J , LIU ZHI-REN
发明人： YANG JENNY J , LIU ZHI-REN
IPC分类号： A61K49/16
CPC分类号： A61K49/14 , A61K49/085
摘要： A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.
摘要翻译：具有对比度蛋白质的造影剂具有对比性质和至少一种靶向部分，其中所述至少一种靶向部分可操作地连接或引入对比蛋白。包括靶向造影剂和制备这些药剂的方法。

55. 发明申请

WO2006091949A3 PHOSPHORYLATED P68 RNA HELICASE AS A MARKER FOR CANCER AND CANCER METASTASIS 审中-公开
公开(公告)号：WO2006091949A3
公开(公告)日：2006-08-31
申请号：PCT/US2006/006948
申请日：2006-02-24
申请人： GEORGIA STATE UNIVERSITY , LIU, Zhi-Ren
发明人： LIU, Zhi-Ren
IPC分类号： G01N33/574
摘要： A method for determining the presence of cancer cells in a tissue sample or cell sample by detecting the presence of phosphorylated p68 RNA helicase in the sample. Further, a method for determining the presence of metastatic cancer cells in a tissue sample or cell sample by detecting the level of phosphorylated P68 RNA helicase in the sample such that a greater level of the phosphorylated protein in the sample as compared to non-metastatic cells is an indication of the metastatic cancer cells in the sample.

56. 发明申请

WO2004077023A2 HIGH-THROUGHPUT METHODS FOR DETERMINING ELECTRON DENSITY DISTRIBUTIONS AND STRUCTURES OF CRYSTALS 审中-公开
标题翻译：用于确定电子密度分布和晶体结构的高通量方法
公开(公告)号：WO2004077023A2
公开(公告)日：2004-09-10
申请号：PCT/US2004005933
申请日：2004-02-27
申请人： UNIV GEORGIA RES FOUND , LIN DAWEI , LIU ZHI-JIE , PRAISSMAN JEREMY , ROSE JOHN P , TEMPEL WOLFRAM , WANG BI-CHENG
发明人： LIN DAWEI , LIU ZHI-JIE , PRAISSMAN JEREMY , ROSE JOHN P , TEMPEL WOLFRAM , WANG BI-CHENG
IPC分类号： G01N20060101 , G01N23/207 , G06F19/00 , G06F19/16 , G06F19/28 , G01N
CPC分类号： G01N23/207 , G01N2223/0566 , G06F19/16 , G06F19/28 , G06F19/703
摘要： Disclosed are high-throughput methods for determining crystal structures from X-ray diffraction data, for example high-throughput crystal structure determination methods employing flexible, high-throughput modular computational pipelines, such as Bioperl computational pipelines. High-throughput methods for determining crystal structures can be fully or partially automated, and can be fully or partially computer executed. Crystal structure determination methods employing a pipeline interface, work flow manager and/or output parsers can be used to optimize the amount of structural information derived from an X-ray diffraction data set and increase the efficiency of calculating crystal structures from X-ray diffraction data.
摘要翻译：公开了用于从X射线衍射数据确定晶体结构的高通量方法，例如采用灵活的高通量模块计算管线（例如Bioperl计算管线）的高通量晶体结构确定方法。用于确定晶体结构的高通量方法可以完全或部分自动化，并且可以完全或部分地计算机执行。可以使用采用流水线接口，工作流程管理器和/或输出解析器的晶体结构确定方法来优化从X射线衍射数据集得到的结构信息量，并且增加从X射线衍射数据计算晶体结构的效率。

57. 发明申请

WO2004041843A3 HOP - A NOVEL CARDIAC-RESTRICTED TRANSCRIPTIONAL FACTOR POTENTIALLY USEFUL FOR CARDIAC REGENERATION AND SPECIFICATION 审中-公开
标题翻译： HOP - 一种新的心脏限制性转录因子，潜在可用于心脏再生和规格
公开(公告)号：WO2004041843A3
公开(公告)日：2004-07-22
申请号：PCT/US0315482
申请日：2003-05-16
申请人： UNIV TEXAS , OLSON ERIC , LIU ZHI-PING , PASSIER ROBERT
发明人： OLSON ERIC , LIU ZHI-PING , PASSIER ROBERT
IPC分类号： A61K38/00 , A61K48/00 , C07H21/04 , C07K14/47 , C12Q1/68 , A61K38/17 , A61K39/395 , C07H21/00 , C07K14/435 , C12N5/16
CPC分类号： C07H21/04 , A01K2217/05 , A61K38/00 , A61K48/00 , C07K14/4702 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to HOP, a cardiac homeodomain protein that regulates cell differentiation and cell proliferation in cardiac, liver, lung and neuronal cells. Also disclosed are methods of using the gene and protein to treat and diagnose cardiovascular and neuronal diseases, as well as in screening methods.
摘要翻译：本发明涉及调节心脏，肝脏，肺和神经元细胞中细胞分化和细胞增殖的心脏同源结构域蛋白HOP。还公开了使用该基因和蛋白质来治疗和诊断心血管和神经元疾病以及筛选方法的方法。

58. 发明申请

WO2004041843A2 HOP - A NOVEL CARDIAC-RESTRICTED TRANSCRIPTIONAL FACTOR POTENTIALLY USEFUL FOR CARDIAC REGENERATION AND SPECIFICATION 审中-公开
标题翻译： HOP - 一种新型心脏限制性转录因子，可用于心脏再生和规范
公开(公告)号：WO2004041843A2
公开(公告)日：2004-05-21
申请号：PCT/US2003/015482
申请日：2003-05-16
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , OLSON, Eric , LIU, Zhi-Ping , PASSIER, Robert
发明人： OLSON, Eric , LIU, Zhi-Ping , PASSIER, Robert
IPC分类号： C07K
CPC分类号： C07H21/04 , A01K2217/05 , A61K38/00 , A61K48/00 , C07K14/4702 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to HOP, a cardiac homeodomain protein that regulates cell differentiation and cell proliferation in cardiac, liver, lung and neuronal cells. Also disclosed are methods of using the gene and protein to treat and diagnose cardiovascular and neuronal diseases, as well as in screening methods.
摘要翻译：本发明涉及HOP，即心脏同源域蛋白质，其调节心脏，肝脏，肺和神经元细胞中的细胞分化和细胞增殖。还公开了使用该基因和蛋白质治疗和诊断心血管和神经元疾病以及筛选方法的方法。

59. 发明申请

WO2002095016A2 CHAMP - A NOVEL CARDIAC HELICASE-LIKE FACTOR 审中-公开
标题翻译： CHAMP - 一个新的CARDIAC HELICASE-like因子
公开(公告)号：WO2002095016A2
公开(公告)日：2002-11-28
申请号：PCT/US2002/022511
申请日：2002-02-15
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , OLSON, Eric , LIU, Zhi-Ping
发明人： OLSON, Eric , LIU, Zhi-Ping
IPC分类号： C12N9/00
CPC分类号： C12N9/90 , A01K2217/05 , A61K38/00 , A61K48/00 , C12N2799/021
摘要： The present invention relates to a new polypeptide and the gene encoding therefore, said gene being regulated in cardiac tissue by the transcription factor MEF2C. This polypeptide, CHAMP (cardiac helicase activated by MEF2 protein), bears striking resemblance to a number of other helicase proteins and appears to play a role in RNA processing and transcriptional control in heart muscle. For example, CHAMP has been demonstrated to inhibit both hypertrophy of primary cardiomyocytes and proliferation of non-cardiac cells. Also disclosed are methods of using the gene and protein in drug screening and therapy, including, for example, use of the gene in gene therapy to treat cardiovascular disease.
摘要翻译：本发明涉及一种新的多肽和所编码的基因，所述基因通过转录因子MEF2C在心脏组织中调节。这种多肽CHAMP（由MEF2蛋白激活的心脏解旋酶）与许多其他解旋酶蛋白质具有显着的相似性，并且似乎在心肌的RNA加工和转录控制中起作用。例如，CHAMP已被证明能抑制原发性心肌细胞的肥大和非心脏细胞的增殖。还公开了在药物筛选和治疗中使用基因和蛋白质的方法，包括例如在基因治疗中使用基因治疗心血管疾病。

60. 发明申请

WO0216396A9 MAMMALIAN RH TYPE B GLYCOPROTEIN ION TRANSPORTER 审中-公开
公开(公告)号：WO0216396A9
公开(公告)日：2002-09-26
申请号：PCT/US0125881
申请日：2001-08-17
申请人： NEW YORK BLOOD CT INC , HUANG CHENG-HAN , LIU ZHI
发明人： HUANG CHENG-HAN , LIU ZHI
IPC分类号： C07K14/705 , C12N15/12 , C07K
CPC分类号： C07K14/705 , C07K2319/00
摘要： The present invention provides nucleic acid sequences encoding novel mammalian nonerythroid Rh glycoprotein homologues, Rhbg including the human homologue RhBG. These RhBG, Rhbg glycoproteins are polytypic transporter-type proteins with 12 transmembrane domains and are predominantly expressed as a single major form in kidney, and as multiple forms in liver, skin and ovaries. Also provided are recombinant vectors and host vector systems containing these nucleic acid sequences, as well as fusion proteins incorporating Rhbg, RhBG or fragments of each. The invention further provides methods of detection of Rhbg and RhBG glycoproteins and also methods of detecting nucleic acids encoding Rhbg and RhBG.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式